JP7223502B6 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP7223502B6
JP7223502B6 JP2018030208A JP2018030208A JP7223502B6 JP 7223502 B6 JP7223502 B6 JP 7223502B6 JP 2018030208 A JP2018030208 A JP 2018030208A JP 2018030208 A JP2018030208 A JP 2018030208A JP 7223502 B6 JP7223502 B6 JP 7223502B6
Authority
JP
Japan
Prior art keywords
group
polymer
cancer
compound
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018030208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019142823A5 (enExample
JP7223502B2 (ja
JP2019142823A (ja
Inventor
一則 片岡
宏昭 喜納
サビーナ カダール
オラシオ カブラル
光太朗 林
伸宏 西山
宏泰 武元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kawasaki Institute of Industrial Promotion
Original Assignee
Kawasaki Institute of Industrial Promotion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kawasaki Institute of Industrial Promotion filed Critical Kawasaki Institute of Industrial Promotion
Priority to JP2018030208A priority Critical patent/JP7223502B6/ja
Priority to PCT/JP2019/006780 priority patent/WO2019163943A1/ja
Publication of JP2019142823A publication Critical patent/JP2019142823A/ja
Publication of JP2019142823A5 publication Critical patent/JP2019142823A5/ja
Publication of JP7223502B2 publication Critical patent/JP7223502B2/ja
Application granted granted Critical
Publication of JP7223502B6 publication Critical patent/JP7223502B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018030208A 2018-02-22 2018-02-22 医薬組成物 Active JP7223502B6 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018030208A JP7223502B6 (ja) 2018-02-22 2018-02-22 医薬組成物
PCT/JP2019/006780 WO2019163943A1 (ja) 2018-02-22 2019-02-22 医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018030208A JP7223502B6 (ja) 2018-02-22 2018-02-22 医薬組成物

Publications (4)

Publication Number Publication Date
JP2019142823A JP2019142823A (ja) 2019-08-29
JP2019142823A5 JP2019142823A5 (enExample) 2021-01-14
JP7223502B2 JP7223502B2 (ja) 2023-02-16
JP7223502B6 true JP7223502B6 (ja) 2024-02-08

Family

ID=67688423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018030208A Active JP7223502B6 (ja) 2018-02-22 2018-02-22 医薬組成物

Country Status (2)

Country Link
JP (1) JP7223502B6 (enExample)
WO (1) WO2019163943A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333659B (zh) * 2019-09-19 2021-04-06 杭州科兴生物化工有限公司 一类星孢菌素类衍生物及其制备方法和应用
CN116041371B (zh) * 2023-01-29 2024-04-19 杭州科兴生物化工有限公司 7-羰基星孢菌素衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506000A (ja) 2005-08-25 2009-02-12 クレアビリス・セラピューティクス・エスピーエー Ｋ‐２５２ａおよびその誘導体のポリマー結合体
WO2016024595A1 (ja) 2014-08-11 2016-02-18 国立大学法人東京大学 エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032974A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Carbazole derivatives as agents against multi-drug resistance
EP3971227A1 (en) * 2016-08-23 2022-03-23 Kawasaki Institute of Industrial Promotion Polymer, method for producing polymer, and drug conjugate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506000A (ja) 2005-08-25 2009-02-12 クレアビリス・セラピューティクス・エスピーエー Ｋ‐２５２ａおよびその誘導体のポリマー結合体
WO2016024595A1 (ja) 2014-08-11 2016-02-18 国立大学法人東京大学 エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CONSEIL G. et al.，Protein Kinase C Effectors Bind to Multidrug ABC Transporters and Inhibit Their Activity，Biochemistry，2001年，40(8), 2564-2571，DOI: 10.1021/bi002453m, アブストラクト、図１－８
FESTUCCIA C. et al.，Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules gui，Oncol Rep.，2007年，18(2), 503-511，図５、６
KONG L. et al.，Structural pharmacological studies on EGFR T790M/C797S，Biochem Biophys Res Commun.，2017年，488(2), 266-272，doi: 10.1016/j.bbrc.2017.04.138, アブストラクト、図１、表１
LAI P. et al.，Lestaurtinib is Cytotoxic to Oxaliplatin-resistant Transitional Cell Carcinoma Cell Line T24 In Vitr，Tzu Chi Medical Journal，2010年，22(3), 125-130，https://doi.org/10.1016/S1016-3190(10)60056-0, 図１、３
LEE H. et al.，Noncovalent Wild-type-Sparing Inhibitors of EGFR T790M，Cancer Discov.，2012年，3(2), 168-181，doi: 10.1158/2159-8290.CD-12-0357, 図１－３
MIYAMOTO K. et al.，Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo，Cancer Res.，1993年，53(7), 1555-1559，表１－３、図３，４
SHI Z. et al.，S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by，Cancer Res.，2001年，61(3), 1065-1072，図３－６
SONG X. et al.，Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EG，J Mol Recognit.，2017年，30(4)，doi: 10.1002/jmr.2590, アブストラクト、表１
UTZ I. et al.，The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, revers，Int J Cancer.，1994年，57(1), 104-110，図１－９
YAO J. et al.，Systematic profiling of chemotherapeutic drug response to EGFR gatekeeper mutation in non-small cell，Comput Biol Chem.，2016年，64, 126-133，doi: 10.1016/j.compbiolchem.2016.05.009, 表４

Also Published As

Publication number Publication date
JP7223502B2 (ja) 2023-02-16
WO2019163943A1 (ja) 2019-08-29
JP2019142823A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
JP6013424B2 (ja) Ｈｐｍａ−ドセタキセルコンジュゲートおよびその使用
Pan et al. PEGylated dendritic diaminocyclohexyl-platinum (II) conjugates as pH-responsive drug delivery vehicles with enhanced tumor accumulation and antitumor efficacy
KR101721865B1 (ko) 항암제의 전달을 위한 폴리머 시스템
JP2010526091A5 (enExample)
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
Zhao et al. An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors
JP6229865B2 (ja) エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物
JP6965248B2 (ja) ポリマー、ポリマーの製造方法、及び薬物複合体
US20230277677A1 (en) Polymeric conjugates and uses thereof
Zhou et al. A linear polyethylenimine (LPEI) drug conjugate with reversible charge to overcome multidrug resistance in cancer cells
WO2014084378A1 (ja) 環状ｒｇｄ配列含有ペプチドを含む抗癌剤
JP7223502B6 (ja) 医薬組成物
CN105131039B (zh) 一种喜树碱类磷脂化合物、其药物组合物及应用
JP7575731B2 (ja) 結合体、及び癌治療剤
JP6580030B2 (ja) カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途
CN117304424A (zh) 一种还原响应性的纳米递送系统及其在制备治疗耐药性肿瘤的药物中的用途
CN111868093A (zh) 抗癌剂
TW201521787A (zh) 烏米莫司（ｕｍｉｒｏｌｉｍｕｓ）及其衍生物於治療癌症之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230206

R150 Certificate of patent or registration of utility model

Ref document number: 7223502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150